Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
DX1JVA
|
||||
| Drug Name |
N-(4-(chlorodifluoromethoxy)phenyl)-5-(2-(2-(pyridin-4-yl)ethyl)pyridin-3-yl)-1,3,4-oxadiazol-2-amine
|
||||
| Synonyms |
CHEMBL205502
|
||||
| Indication | Discovery agent | Investigative | [1587926] | ||
| Formula |
C21H16ClF2N5O2
|
||||
| Canonical SMILES |
FC(F)(Cl)Oc1ccc(Nc2oc(nn2)c3cccnc3CCc4ccncc4)cc1
|
||||
| InChI |
InChI=1S/C21H16ClF2N5O2/c22-21(23,24)31-16-6-4-15(5-7-16)27-20-29-28-19(30-20)17-2-1-11-26-18(17)8-3-14-9-12-25-13-10-14/h1-2,4-7,9-13H,3,8H2,(H,27,29)
|
||||
| InChIKey |
BJGRIFQHDVCHMB-UHFFFAOYSA-N
|
||||
| Target and Pathway | |||||
| Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | [1587926] | ||
| Vascular endothelial growth factor receptor 1 | Target Info | [1587926] | |||
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| VEGF signaling pathway | |||||
| Focal adhesion | |||||
| Proteoglycans in cancerhsa04014:Ras signaling pathway | |||||
| HIF-1 signaling pathway | |||||
| Transcriptional misregulation in cancer | |||||
| Rheumatoid arthritis | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| PANTHER Pathway | Angiogenesis | ||||
| VEGF signaling pathway | |||||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
| Beta3 integrin cell surface interactions | |||||
| Signaling events mediated by TCPTP | |||||
| SHP2 signaling | |||||
| S1P1 pathway | |||||
| VEGF and VEGFR signaling network | |||||
| Integrins in angiogenesis | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Notch-mediated HES/HEY networkglypican_1pathway:Glypican 1 network | |||||
| S1P3 pathway | |||||
| VEGFR1 specific signals | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.